Verdiperstat
- Generic Name
- Verdiperstat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H15N3O2S
- CAS Number
- 890655-80-8
- Unique Ingredient Identifier
- TT3345YXVR
- Background
Verdiperstat has been used in trials studying the basic science and treatment of Multiple System Atrophy (MSA).
- Associated Conditions
- -
- Associated Therapies
- -
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Peter Ljubenkov, MD
- Target Recruit Count
- 64
- Registration Number
- NCT05184569
- Locations
- ๐บ๐ธ
UCSF Memory and Aging Center, San Francisco, California, United States
๐บ๐ธNorthwestern University, Chicago, Illinois, United States
๐บ๐ธMayo Clinic, Rochester, Minnesota, United States
Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT04616456
- Locations
- ๐บ๐ธ
Movement Disorders Clinic, 60 Fenwood Road, Boston, Massachusetts, United States
HEALEY ALS Platform Trial - Regimen B Verdiperstat
- Conditions
- Interventions
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Merit E. Cudkowicz, MD
- Target Recruit Count
- 167
- Registration Number
- NCT04436510
- Locations
- ๐บ๐ธ
Healey Center for ALS at Mass General, Boston, Massachusetts, United States
HEALEY ALS Platform Trial - Master Protocol
- Conditions
- Interventions
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Merit E. Cudkowicz, MD
- Target Recruit Count
- 1500
- Registration Number
- NCT04297683
- Locations
- ๐บ๐ธ
Neurology Associates, P.C./Somnos Clinical Research, Lincoln, Nebraska, United States
๐บ๐ธKaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
๐บ๐ธJohns Hopkins University, Baltimore, Maryland, United States
Study of BHV-3241 in Participants With Multiple System Atrophy
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Biohaven Pharmaceuticals, Inc.
- Target Recruit Count
- 421
- Registration Number
- NCT03952806
- Locations
- ๐บ๐ธ
UT Southwestern Medical Center, Dallas, Texas, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.